$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

$ctor Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-Q Financial Statement

#000121390025014320 Filed on February 14, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2023 Q4
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$244.1K
YoY Change			76.76%
% of Gross Profit
Research & Development		$1.265M	$1.148M
YoY Change		10.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$6.395M	$244.1K
YoY Change		2519.38%	76.76%
Operating Profit
YoY Change
Interest Expense			$1.277M
YoY Change			146.18%
% of Operating Profit
Other Income/Expense, Net		$30.37K	$30.37K
YoY Change		0.0%
Pretax Income		-$6.395M	$1.033M
YoY Change		-718.86%	171.35%
Income Tax		$264.2K	$144.0K
% Of Pretax Income			13.94%
Net Earnings		-$6.659M	$1.033M
YoY Change		-744.44%	171.35%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.09	-$0.07
Diluted Earnings Per Share		-$0.09	$0.12
COMMON SHARES
Basic Shares Outstanding	71.55M shares	71.55M shares	8.941M shares
Diluted Shares Outstanding		71.55M shares	67.50M shares

Balance Sheet

Concept	2024 Q4	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$32.75K
YoY Change		-88.67%
Cash & Equivalents	$112.00	$32.75K
Short-Term Investments
Other Short-Term Assets		$25.45K
YoY Change		-71.14%
Inventory	$14.38M
Prepaid Expenses	$2.700M	$25.45K
Receivables
Other Receivables
Total Short-Term Assets	$17.08M	$58.20K
YoY Change	29249.62%	-84.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$72.57M
YoY Change		7.01%
Other Assets
YoY Change
Total Long-Term Assets	$73.40M	$72.57M
YoY Change	1.15%	7.01%
TOTAL ASSETS
Total Short-Term Assets	$17.08M	$58.20K
Total Long-Term Assets	$73.40M	$72.57M
Total Assets	$90.48M	$72.62M
YoY Change	24.59%	6.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.875M
YoY Change
Accrued Expenses	$6.229M	$375.9K
YoY Change	1557.05%	1080.55%
Deferred Revenue
YoY Change
Short-Term Debt		$1.320M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$43.40M	$2.046M
YoY Change	2021.44%	6325.94%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.40M	$2.046M
Total Long-Term Liabilities		$0.00
Total Liabilities	$49.19M	$2.046M
YoY Change	2304.58%	6325.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$45.94M	-$1.988M
YoY Change	2211.07%	-675.71%
Common Stock	$7.155K	$167.00
YoY Change	4184.43%	-30.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.29M	-$1.988M
YoY Change
Total Liabilities & Shareholders Equity	$90.48M	$72.62M
YoY Change	24.59%	6.5%

Cashflow Statement

Concept	2024 Q4	2023 Q4
OPERATING ACTIVITIES
Net Income	-$6.659M	$1.033M
YoY Change	-744.44%	171.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$218.8K
YoY Change		356.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$660.0K
YoY Change		-99.02%
Cash From Investing Activities		-$660.0K
YoY Change		-99.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		885.0K
YoY Change		-98.69%
NET CHANGE
Cash From Operating Activities		-218.8K
Cash From Investing Activities		-660.0K
Cash From Financing Activities		885.0K
Net Change In Cash	$0.00	6.230K
YoY Change	-100.0%	-97.85%
FREE CASH FLOW
Cash From Operating Activities		-$218.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q4	dei	Document Type DocumentType	10-Q
CY2024Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q4	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q4	dei	Entity File Number EntityFileNumber	001-41534
CY2024Q4	dei	Entity Registrant Name EntityRegistrantName	Citius Oncology, Inc.
CY2024Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-4362660
CY2024Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
CY2024Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
CY2024Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
CY2024Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
CY2024Q4	dei	City Area Code CityAreaCode	(908)
CY2024Q4	dei	Local Phone Number LocalPhoneNumber	967-6677
CY2024Q4	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value
CY2024Q4	dei	Trading Symbol TradingSymbol	CTOR
CY2024Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q4	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q4	dei	Entity Shell Company EntityShellCompany	false
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71552402	shares
CY2024Q4	us-gaap	Cash Cash	112	usd
CY2024Q3	us-gaap	Cash Cash	112	usd
CY2024Q4	us-gaap	Inventory Net InventoryNet	14381369	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	8268766	usd
CY2024Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2700000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2700000	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	17081481	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	10968878	usd
CY2024Q4	ctor	Inprocess Research And Development Noncurrent InprocessResearchAndDevelopmentNoncurrent	73400000	usd
CY2024Q3	ctor	Inprocess Research And Development Noncurrent InprocessResearchAndDevelopmentNoncurrent	73400000	usd
CY2024Q4	us-gaap	Other Assets OtherAssets	73400000	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	73400000	usd
CY2024Q4	us-gaap	Assets Assets	90481481	usd
CY2024Q3	us-gaap	Assets Assets	84368878	usd
CY2024Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5874577	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3711622	usd
CY2024Q4	ctor	License Payable LicensePayable	28400000	usd
CY2024Q3	ctor	License Payable LicensePayable	28400000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6228612	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	43399518	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32700428	usd
CY2024Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1992240	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1728000	usd
CY2024Q4	us-gaap	Liabilities Liabilities	49191869	usd
CY2024Q3	us-gaap	Liabilities Liabilities	38228539	usd
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71552402	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71552402	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71552402	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71552402	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	7155	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	7155	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87220249	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85411771	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45937792	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39278587	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	41289612	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	46140339	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90481481	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84368878	usd
CY2024Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1264508	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1148495	usd
CY2024Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3321979	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1517908	usd
CY2024Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1808478	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1917000	usd
CY2024Q4	us-gaap	Operating Expenses OperatingExpenses	6394965	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	4583403	usd
CY2024Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6394965	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4583403	usd
CY2024Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	264240	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-6659205	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4727403	usd
CY2024Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2024Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71552402	shares
CY2024Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71552402	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67500000	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67500000	shares
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	46140339	usd
CY2024Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1808478	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-6659205	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	41289612	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	25535660	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1917000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4727403	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	22725257	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-6659205	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4727403	usd
CY2024Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1808478	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1917000	usd
CY2024Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	264240	usd
CY2023Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	144000	usd
CY2024Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6112603	usd
CY2024Q4	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2162955	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1084027	usd
CY2024Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6228612	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-199155	usd
CY2024Q4	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	2307523	usd
CY2023Q4	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	3949585	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112	usd
CY2024Q3	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	71552402	shares
CY2024Q4	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	2753795	usd
CY2024Q4	us-gaap	Other Liabilities OtherLiabilities	559015	usd
CY2024	ctor	Related Transaction Costs RelatedTransactionCosts	2358780	usd
CY2024	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	3827944	usd
CY2024	ctor	Additional Paid In Capital Receivables AdditionalPaidInCapitalReceivables	33180961	usd
CY2024	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3800111	usd
CY2024Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates -</i> The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development, stock-based compensation and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</span></p>
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-6659205	usd
CY2024Q4	ctor	Working Capital WorkingCapital	26318037	usd
CY2024Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6134895	usd
CY2024Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8246474	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6134895	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2133862	usd
CY2024Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2700000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2700000	usd
CY2024Q4	ctor	Commercial Sales Milestones CommercialSalesMilestones	300000000	usd
CY2024Q4	ctor	Net Sales Percentage NetSalesPercentage	0.50	pure
CY2024Q4	ctor	Development Milestone Payments DevelopmentMilestonePayments	27500000	usd
CY2024Q4	ctor	Net Product Sales Payment NetProductSalesPayment	22000000	usd
CY2024Q4	ctor	Reimburse Amount ReimburseAmount	2650000	usd
CY2024Q3	ctor	Development Milestone Payments DevelopmentMilestonePayments	33400000	usd
CY2024Q3	ctor	License Payable Current LicensePayableCurrent	5000000	usd
CY2024Q3	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	33400000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15000000	shares
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15000000	shares
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P10Y
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12750000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.15
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M10D
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5750000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.07
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18500000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.81
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M19D
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	470000	usd
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4750000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.15
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y6M7D
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.8
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P10Y
CY2024Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1808478	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1917000	usd
CY2024Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14393428	usd
CY2024Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M13D
CY2024Q4	us-gaap	Payments For Fees PaymentsForFees	250000	usd
CY2024Q4	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	17300000	usd
CY2024Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	4500000	usd
CY2024Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	2900000	usd
CY2024Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	1600000	usd
CY2024Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	567937	usd
CY2024Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	480000	usd
CY2024Q4	us-gaap	Other Expenses OtherExpenses	30368	usd
CY2023Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	422282	usd
CY2023Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	483063	usd
CY2023Q4	us-gaap	Other Expenses OtherExpenses	30368	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3800111	usd
CY2024Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10000000	usd
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent		usd
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q4	us-gaap	Revenues Revenues		usd
CY2023Q4	us-gaap	Revenues Revenues		usd
CY2023Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2024Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect		usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect		usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001851484
CY2024Q4	dei	Amendment Flag AmendmentFlag	false
CY2024Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30

Files In Submission

Name	View Source	Status
0001213900-25-014320-index-headers.html	Edgar Link	pending
0001213900-25-014320-index.html	Edgar Link	pending
0001213900-25-014320.txt	Edgar Link	pending
0001213900-25-014320-xbrl.zip	Edgar Link	pending
ctor-20241231.xsd	Edgar Link	pending
ctor-20241231_cal.xml	Edgar Link	unprocessable
ctor-20241231_def.xml	Edgar Link	unprocessable
ea0230776-10q_citius.htm	Edgar Link	pending
ea023077601ex31-1_citius.htm	Edgar Link	pending
ea023077601ex31-2_citius.htm	Edgar Link	pending
ea023077601ex32-1_citius.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0230776-10q_citius_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctor-20241231_lab.xml	Edgar Link	unprocessable
ctor-20241231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

2025 Q1 Form 10-Q Financial Statement

#000121390025014320 Filed on February 14, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR CITIUS ONCOLOGY, INC. Stock $ctor

2025 Q1 Form 10-Q Financial Statement

#000121390025014320 Filed on February 14, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor